Proton-pump inhibitor therapy and small bowel bacterial contamination;Protonpumpagátló kezelés és a vékonybél bakteriális kontaminációja

Orvosi Hetilap

Volumn 153, Issue 33, 2012, Pages 1287-1293

  Hamvas, József ^a  

^a Bajcsy Zsilinszky Kórház I Belgyógyászat Gasztroenterológia ^*  (Hungary)

Author keywords

antibiotics; proton pump inhibitor; rifaximin; SIBO; small bowel contamination

Indexed keywords

ANTIBIOTIC AGENT; PROTON PUMP INHIBITOR; RIFAXIMIN;

ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL OVERGROWTH; BACTERIUM CONTAMINATION; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE COURSE; HYDROGEN BREATH TEST; LONG TERM CARE; NON INVASIVE PROCEDURE; SMALL INTESTINAL BACTERIAL OVERGROWTH; SMALL INTESTINE DISEASE;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; BREATH TESTS; DRUG ADMINISTRATION SCHEDULE; GASTROINTESTINAL AGENTS; HUMANS; INTESTINE, SMALL; PROBIOTICS; PROTON PUMP INHIBITORS; RIFAMYCINS; TIME FACTORS;

EID: 84865224808     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2012.29419     Document Type: Article

References (24)

1. McCarthy, D. M.: Adverse effects of proton pump inhibitor drugs: Clues and conclusions. Curr. Opin. Gastroenterol., 2010, 26, 624-631.
2. Lewis, S. J., Franco, S., Young, G., et al.: Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment. Pharmacol. Ther., 1996, 10, 557-561. (Pubitemid 26254799)
3. Bures, J., Cyrany, J., Kohoutova, S., al.: Small intestinal bacterial overgrowth syndrome. World J. Gastroenterol., 2010, 16, 2978-2990.
4. Ratuapli, S. K., Ellington, T. G., O'Neill, M. T., et al.: Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth. Am. J. Gastroenterol., 2012, 107, 730-735.
5. Rana, S. V., Bhardwaj, S. B.: Small intestinal bacterial overgrowth. Scand. J. Gastroenterol., 2008, 43, 1030-1037.
6. Corazza, G. R., Menozzi, M. G., Strocchi, A., et al.: The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology, 1990, 98, 302-309. (Pubitemid 20037910)
7. Gasbarrini, A., Corazza, G. R., Gasbarrini, G.: Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. Aliment. Pharmacol. Ther., 2009, 29 (Suppl. 1), 1-49.
8. Klaus, J., Spaniol, U., Adler, G., et al.: Small intestinal bacterial overgrowth mimicking acute fl are as a pitfall in patients with Crohn's disease. BMC Gastroenterology, 2009, 9, 61.
9. Castiglione, F., Rispo, A., Di Girolamo, E., et al.: Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease. Aliment. Pharmacol. Ther., 2003, 18, 1107-1112. (Pubitemid 38021596)
10. Petrone, P., Sarkisyan, G., Fernández, M., et al.: Small intestinal bacterial overgrowth in patients with lower gastrointestinal symptoms and a history of previous abdominal surgery. Arch. Surg., 2011, 146, 444-447.
11. Quera, R. P., Quigley, M. M., Madrid, A. M. S., et al.: Small intestinal bacterial overgrowth. An update. Rev. Med. Chile, 2005, 133, 1361-1370.
12. Brennan, M. R., et al.: Bacterial overgrowth and irritable bowel syndrome: Unifying hypothesis or a spurious consequence of proton pump inhibitors Am. J. Gastroenterol., 2008, 103, 2972-2976.
13. Beró, T.: Diagnosis and therapy of lactose intolerance in adults. [A felnttkori laktozintolerancia diagnosztikaja es terapiaja.] LAM, 2003, 13, 277-281. [Hungarian].
14. Pimentel, M., Lembo, A., Chey, W. D.: Rifaximin therapy for patients with irritable bowel syndrome without constipation. N. Engl. J. Med., 2011, 364, 22-32.
15. Quigley, E. M., Quera, R.: Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology, 2006, 130 (2 Suppl. 1), 78-90.
16. Demeter, P.: Probiotics in gastrointestinal diseases. [A probiotikumok alkalmazasanak lehetsegei emesztszervi betegsegekben.] LAM, 2006, 16, 41-47. [Hungarian].
17. Lauritano, E. C., Gabrielli, M., Scarpellini, E., et al.: Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur. Rev. Med. Pharmacol. Sci., 2009, 13, 111-116.
18. Pimentel, M.: Review of rifaximin as treatment for SIBO and IBS. Expert Opin. Investig. Drugs, 2009, 18, 349-358.
19. Novák, J.: Bacterial contamination and irritabile bowel syndrome. [A bakterialis kontaminacio es az irritabilis bel szindroma.] LAM, 2012, 22, 300-303. [Hungarian].
20. Majewsky, M.: Effi cacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth. Am. J. Med. Sci., 2007, 333, 266-270.
21. Compare, D., Pica, L., Rocco, A., et al.: Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur. J. Clin. Invest., 2011, 41, 380-386.
22. Lombardo, L., Foti, M., Ruggia, O., et al.: Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin. Gastroenterol. Hepatol., 2010, 8 (6), 504-508.
23. Johnson, D. A., Lombardo, L., Foti, M., Ruggia, O., et al.: Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin. Gastroenterol. Hepatol., 2010, 8, 504-508.
24. Székely, Gy., Hamvas, J., Bárkányi, A.: Effect of proton pump inhibitor therapy on intestinal bacteria. [Protonpumpagatlo kezeles hatasa a belfl orara.] Magyar Gasztroenterologiai Tarsasag Nagygylese, 2010. abstr. 239. [Hungarian]